Victoria Clapes

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

CD200 genotype is associated with clinical outcome of patients with multiple myeloma.

CD200 genotype is associated with clinical outcome of patients with multiple myeloma.

Journal: Frontiers in immunology

Published: July 03, 2023

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.

Journal: Frontiers in immunology

Published: February 03, 2023

Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas.

Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas.

Journal: Clinical lymphoma, myeloma & leukemia

Published: February 02, 2022

A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.

A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.

Journal: Bone marrow transplantation

Published: May 05, 2021

Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma.

Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma.

Journal: European journal of haematology

Published: February 05, 2021

Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience.

Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience.

Journal: Anti-cancer drugs

Published: December 17, 2020

The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting.

The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting.

Journal: Cancer reports (Hoboken, N.J.)

Published: December 09, 2020

Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?

Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?

Journal: Clinical lymphoma, myeloma & leukemia

Published: November 15, 2018

Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.

Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.

Journal: European journal of haematology

Published: September 27, 2018

Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.

Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.

Journal: European journal of haematology

Published: January 13, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026